<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32307524</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>ALS-associated genes in SCA2 mouse spinal cord transcriptomes.</ArticleTitle><Pagination><StartPage>1658</StartPage><EndPage>1672</EndPage><MedlinePgn>1658-1672</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddaa072</ELocationID><Abstract><AbstractText>The spinocerebellar ataxia type 2 (SCA2) gene ATXN2 has a prominent role in the pathogenesis and treatment of amyotrophic lateral sclerosis (ALS). In addition to cerebellar ataxia, motor neuron disease is often seen in SCA2, and ATXN2 CAG repeat expansions in the long normal range increase ALS risk. Also, lowering ATXN2 expression in TDP-43 ALS mice prolongs their survival. Here we investigated the ATXN2 relationship with motor neuron dysfunction in vivo by comparing spinal cord (SC) transcriptomes reported from TDP-43 and SOD1 ALS mice and ALS patients with those from SCA2 mice. SC transcriptomes were determined using an SCA2 bacterial artificial chromosome mouse model expressing polyglutamine expanded ATXN2. SCA2 cerebellar transcriptomes were also determined, and we also investigated the modification of gene expression following treatment of SCA2 mice with an antisense oligonucleotide (ASO) lowering ATXN2 expression. Differentially expressed genes (DEGs) defined three interconnected pathways (innate immunity, fatty acid biosynthesis and cholesterol biosynthesis) in separate modules identified by weighted gene co-expression network analysis. Other key pathways included the complement system and lysosome/phagosome pathways. Of all DEGs in SC, 12.6% were also dysregulated in the cerebellum. Treatment of mice with an ATXN2 ASO also modified innate immunity, the complement system and lysosome/phagosome pathways. This study provides new insights into the underlying molecular basis of SCA2 SC phenotypes and demonstrates annotated pathways shared with TDP-43 and SOD1 ALS mice and ALS patients. It also emphasizes the importance of ATXN2 in motor neuron degeneration and confirms ATXN2 as a therapeutic target.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scoles</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dansithong</LastName><ForeName>Warunee</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pflieger</LastName><ForeName>Lance T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Utah, 421 Wakara Way, Salt Lake City, UT 84108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Sharan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandelman</LastName><ForeName>Mandi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Karla P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>C Frank</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulst</LastName><ForeName>Stefan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, 175 North Medical Drive East, 5th Floor, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS033123</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS103883</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS081182</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS033123</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097903</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS103009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="N">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32307524</ArticleId><ArticleId IdType="pmc">PMC7322574</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddaa072</ArticleId><ArticleId IdType="pii">5822587</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pulst S.M., Nechiporuk A., Nechiporuk T., Gispert S., Chen X.N., Lopes-Cendes I., Pearlman S., Starkman S., Orozco-Diaz G., Lunkes A. et al. (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet., 14, 269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896555</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez M., McClain M.E., Martinez R.A., Snow K., Lipe H., Ravits J., Bird T.D. and La Spada A.R. (2000) Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology, 55, 569&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">10953195</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M. et al. (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature, 466, 1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuenschwander A.G., Thai K.K., Figueroa K.P. and Pulst S.M. (2014) Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis. JAMA Neurol., 71, 1529&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4939089</ArticleId><ArticleId IdType="pubmed">25285812</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero W., Shatunov A., Stahl D., Shoai M., Rheenen W., Jones A.R., Al-Sarraj S., Andersen P.M., Bonini N.M., Conforti F.L. et al. (2017) ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol. Aging, 51, &#x2013;178 e171, 178 e179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5302215</ArticleId><ArticleId IdType="pubmed">28017481</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Veldink J.H., Blitterswijk M., Corveleyn A., Vught P.W., Thijs V., Dubois B., Matthijs G., Berg L.H. and Robberecht W. (2011) Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology, 76, 2066&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pubmed">21562247</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles D.R., Meera P., Schneider M.D., Paul S., Dansithong W., Figueroa K.P., Hung G., Rigo F., Bennett C.F., Otis T.S. et al. (2017) Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature, 544, 362&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="pubmed">28405024</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G. et al. (2017) Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature, 544, 367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C., Campanari M.L., Julie Corbier C., Gaucherot A., Kolb-Cheynel I., Oulad-Abdelghani M., Ruffenach F., Page A., Ciura S., Kabashi E. et al. (2016) Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J., 35, 1276&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910533</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan S.M.K., Gendron T.F., Petrucelli L., Hegele R.A. and Strong M.J. (2018) OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. Am. J. Med. Genet. B Neuropsychiatr. Genet., 177, 75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">29080331</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Erchia A.M., Gallo A., Manzari C., Raho S., Horner D.S., Chiara M., Valletti A., Aiello I., Mastropasqua F., Ciaccia L. et al. (2017) Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci. Rep., 7, 10046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres-Benito P., Moreno J., Aso E., Povedano M. and Ferrer I. (2017) Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degeneration. Aging (Albany NY), 9, 823&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391234</ArticleId><ArticleId IdType="pubmed">28283675</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P., Mischel P.S. and Horvath S. (2013) When is hub gene selection better than standard meta-analysis? PLoS One, 8, e61505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629234</ArticleId><ArticleId IdType="pubmed">23613865</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansithong W., Paul S., Figueroa K.P., Rinehart M.D., Wiest S., Pflieger L.T., Scoles D.R. and Pulst S.M. (2015) Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet., 11, e1005182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406435</ArticleId><ArticleId IdType="pubmed">25902068</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M., Fagerberg L., Hallstrom B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson A., Kampf C., Sjostedt E., Asplund A. et al. (2015) Proteomics. Tissue-based map of the human proteome. Science, 347, 1260419.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Stezin A., Venkatesh S.D., Thennarasu K., Purushottam M., Jain S., Yadav R. and Pal P.K. (2018) Non-ataxic manifestations of Spinocerebellar ataxia-2, their determinants and predictors. J. Neurol. Sci., 394, 14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">30196130</ArticleId></ArticleIdList></Reference><Reference><Citation>Recabarren-Leiva D. and Alarcon M. (2018) New insights into the gene expression associated to amyotrophic lateral sclerosis. Life Sci., 193, 110&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">29241710</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X., Chiang P.M., Price D.L. and Wong P.C. (2010) Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl. Acad. Sci. U. S. A., 107, 16325&#x2013;16330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941282</ArticleId><ArticleId IdType="pubmed">20736350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay U., Cotney J., Nagy M., Oh S., Leng J., Mahajan M., Mane S., Fenton W.A., Noonan J.P. and Horwich A.L. (2013) RNA-Seq profiling of spinal cord motor neurons from a presymptomatic SOD1 ALS mouse. PLoS One, 8, e53575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536741</ArticleId><ArticleId IdType="pubmed">23301088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wroe R., Wai-Ling Butler A., Andersen P.M., Powell J.F. and Al-Chalabi A. (2008) ALSOD: the amyotrophic lateral sclerosis online database. Amyotroph. Lateral Scler., 9, 249&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608099</ArticleId></ArticleIdList></Reference><Reference><Citation>Meera P., Pulst S. and Otis T. (2017) A positive feedback loop linking enhanced mGluR function and basal calcium in spinocerebellar ataxia type 2. elife, 6, e26377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444899</ArticleId><ArticleId IdType="pubmed">28518055</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes J.A., Ebner B.A., Duvick L.A., Gao W., Chen G., Orr H.T. and Ebner T.J. (2011) Abnormalities in the climbing fiber-Purkinje cell circuitry contribute to neuronal dysfunction in ATXN1[82Q] mice. J. Neurosci., 31, 12778&#x2013;12789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3178465</ArticleId><ArticleId IdType="pubmed">21900557</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas S. and Chang P. (2014) New PARP targets for cancer therapy. Nat. Rev. Cancer, 14, 502&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4480224</ArticleId><ArticleId IdType="pubmed">24898058</ArticleId></ArticleIdList></Reference><Reference><Citation>West A.P., Khoury-Hanold W., Staron M., Tal M.C., Pineda C.M., Lang S.M., Bestwick M., Duguay B.A., Raimundo N., MacDuff D.A. et al. (2015) Mitochondrial DNA stress primes the antiviral innate immune response. Nature, 520, 553&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409480</ArticleId><ArticleId IdType="pubmed">25642965</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaraweera S.E., O'Keefe L.V., Price G.R., Venter D.J. and Richards R.I. (2013) Distinct roles for toll and autophagy pathways in double-stranded RNA toxicity in a drosophila model of expanded repeat neurodegenerative diseases. Hum. Mol. Genet., 22, 2811&#x2013;2819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690966</ArticleId><ArticleId IdType="pubmed">23525903</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes J.D., Lott M.C., Russell S.L., Moulton V., Sanderson J., Wormstone I.M. and Broadway D.C. (2012) Activation of the innate immune response and interferon signalling in myotonic dystrophy type 1 and type 2 cataracts. Hum. Mol. Genet., 21, 852&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">22062891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lencer W.I., DeLuca H., Grey M.J. and Cho J.A. (2015) Innate immunity at mucosal surfaces: the IRE1-RIDD-RIG-I pathway. Trends Immunol., 36, 401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490948</ArticleId><ArticleId IdType="pubmed">26093676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya S. (2014) Can't RIDD off viruses. Front. Microbiol., 5, 292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4061530</ArticleId><ArticleId IdType="pubmed">24995003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B. and Hur S. (2015) How RIG-I like receptors activate MAVS. Curr. Opin. Virol., 12, 91&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4470786</ArticleId><ArticleId IdType="pubmed">25942693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa H. and Barber G.N. (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature, 455, 674&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804933</ArticleId><ArticleId IdType="pubmed">18724357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Liu X., Cui Y., Tang Y., Chen W., Li S., Yu H., Pan Y. and Wang C. (2014) The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity, 41, 919&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">25526307</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y. and Chen Z.J. (2012) STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal., 5, ra20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549669</ArticleId><ArticleId IdType="pubmed">22394562</ArticleId></ArticleIdList></Reference><Reference><Citation>Suschak J.J., Wang S., Fitzgerald K.A. and Lu S. (2016) A cGAS-independent STING/IRF7 pathway mediates the immunogenicity of DNA vaccines. J. Immunol., 196, 310&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4685033</ArticleId><ArticleId IdType="pubmed">26590319</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Lian Q., Yang B., Yan S., Zhou H., He L., Lin G., Lian Z., Jiang Z. and Sun B. (2015) TRIM30alpha is a negative-feedback regulator of the intracellular DNA and DNA virus-triggered response by targeting STING. PLoS Pathog., 11, e1005012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482643</ArticleId><ArticleId IdType="pubmed">26114947</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., Dansithong W., Figueroa K.P., Scoles D.R. and Pulst S.M. (2018) Staufen1 links RNA stress granules and autophagy in a model of neurodegeneration. Nat. Commun., 9, 3648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128856</ArticleId><ArticleId IdType="pubmed">30194296</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes J.A., Davies M.C. and Collins M.O. (2017) TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol. Brain, 10, 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Muller K., Ludolph A.C., Weishaupt J.H. and Andersen P.M. (2017) Association of Mutations in TBK1 with sporadic and familial amyotrophic lateral sclerosis and Frontotemporal dementia. JAMA Neurol., 74, 110&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">27892983</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Wu H., Wang C., Li Y., Tian H., Siraj S., Sehgal S.A., Wang X., Wang J., Shang Y. et al. (2019) STING directly activates autophagy to tune the innate immune response. Cell Death Differ., 26, 1735&#x2013;1749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748081</ArticleId><ArticleId IdType="pubmed">30568238</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui X., Yang H., Li T., Tan X., Shi P., Li M., Du F. and Chen Z.J. (2019) Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature, 567, 262&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">30842662</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabakaran T., Bodda C., Krapp C., Zhang B.C., Christensen M.H., Sun C., Reinert L., Cai Y., Jensen S.B., Skouboe M.K. et al. (2018) Attenuation of cGAS-STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1. EMBO J., 37, e97858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5897779</ArticleId><ArticleId IdType="pubmed">29496741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadani S.P., Walsh J.T., Smirnov I., Zheng J. and Kipnis J. (2015) The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron, 85, 703&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">25661185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Luo C.L., Li L.L., Ye G.H., Gao C., Wang H.C., Huang W.W., Wang T., Wang Z.F., Ni H. et al. (2017) IL-33 provides Neuroprotection through suppressing apoptotic, Autophagic and NF-kappaB-mediated inflammatory pathways in a rat model of recurrent neonatal seizure. Front. Mol. Neurosci., 10, 423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742123</ArticleId><ArticleId IdType="pubmed">29311813</ArticleId></ArticleIdList></Reference><Reference><Citation>Poppelreuther M., Rudolph B., Du C., Grossmann R., Becker M., Thiele C., Ehehalt R. and Fullekrug J. (2012) The N-terminal region of acyl-CoA synthetase 3 is essential for both the localization on lipid droplets and the function in fatty acid uptake. J. Lipid Res., 53, 888&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329388</ArticleId><ArticleId IdType="pubmed">22357706</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Nonis D., Eich F., Klinkenberg M., Gorospe M., Kotter P., Klein F.A., Kedersha N. and Auburger G. (2016) Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. Biochim. Biophys. Acta, 1862, 1558&#x2013;1569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4967000</ArticleId><ArticleId IdType="pubmed">27240544</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimano H. and Sato R. (2017) SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat. Rev. Endocrinol., 13, 710&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">28849786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Brodesser S., Lutjohann D., Azizov M., Buchmann J., Hintermann E., Sandhoff K., Schurmann A., Nowock J. and Auburger G. (2008) Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum. Mol. Genet., 17, 1465&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pubmed">18250099</ArticleId></ArticleIdList></Reference><Reference><Citation>Meierhofer D., Halbach M., Sen N.E., Gispert S. and Auburger G. (2016) Ataxin-2 (Atxn2)-knock-out mice show branched chain amino acids and fatty acids pathway alterations. Mol. Cell. Proteomics, 15, 1728&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4858951</ArticleId><ArticleId IdType="pubmed">26850065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen N.E., Arsovic A., Meierhofer D., Brodesser S., Oberschmidt C., Canet-Pons J., Kaya Z.E., Halbach M.V., Gispert S., Sandhoff K. et al. (2019) In human and mouse Spino-cerebellar tissue, Ataxin-2 expansion affects Ceramide-Sphingomyelin metabolism. Int. J. Mol. Sci., 20, 5854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6928749</ArticleId><ArticleId IdType="pubmed">31766565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar D.Z., Charar C., Dorfman J., Yadid T., Tafforeau L., Lafontaine D.L. and Gruenbaum Y. (2016) Cell size and fat content of dietary-restricted Caenorhabditis elegans are regulated by ATX-2, an mTOR repressor. Proc. Natl. Acad. Sci. U. S. A., 113, E4620&#x2013;E4629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987808</ArticleId><ArticleId IdType="pubmed">27457958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiehl T.R., Nechiporuk A., Figueroa K.P., Keating M.T., Huynh D.P. and Pulst S.M. (2006) Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem. Biophys. Res. Commun., 339, 17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris H.A., Perry R.J., Moreira G.V., Shulman G.I., Horton J.D. and Kahn C.R. (2017) Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism. Proc. Natl. Acad. Sci. U. S. A., 114, 1189&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293102</ArticleId><ArticleId IdType="pubmed">28096339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L.P., Seemann J., Goldstein J.L. and Brown M.S. (2007) Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap inaccessible to COPII proteins. Proc. Natl. Acad. Sci. U. S. A., 104, 6519&#x2013;6526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851663</ArticleId><ArticleId IdType="pubmed">17428919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Romero D., Swiatek W.I., Dorweiler I., Kikani C.K., Sabic H., Zweifel B.S., McKearn J., Blitzer J.T., Nickols G.A. et al. (2014) PAS kinase drives lipogenesis through SREBP-1 maturation. Cell Rep., 8, 242&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112965</ArticleId><ArticleId IdType="pubmed">25001282</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMille D., Badal B.D., Evans J.B., Mathis A.D., Anderson J.F. and Grose J.H. (2015) PAS kinase is activated by direct SNF1-dependent phosphorylation and mediates inhibition of TORC1 through the phosphorylation and activation of Pbp1. Mol. Biol. Cell, 26, 569&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310746</ArticleId><ArticleId IdType="pubmed">25428989</ArticleId></ArticleIdList></Reference><Reference><Citation>Fessler M.B. (2016) The intracellular cholesterol landscape: dynamic integrator of the immune response. Trends Immunol., 37, 819&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5135597</ArticleId><ArticleId IdType="pubmed">27692616</ArticleId></ArticleIdList></Reference><Reference><Citation>York A.G., Williams K.J., Argus J.P., Zhou Q.D., Brar G., Vergnes L., Gray E.E., Zhen A., Wu N.C., Yamada D.H. et al. (2015) Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell, 163, 1716&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4783382</ArticleId><ArticleId IdType="pubmed">26686653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouzat K., Molinari N., Kantar J., Polge A., Corcia P., Couratier P., Clavelou P., Juntas-Morales R., Pageot N., Lobaccaro J.A. et al. (2018) Liver X receptor genes variants modulate ALS phenotype. Mol. Neurobiol., 55, 1959&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">28244008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobrega C., Mendonca L., Marcelo A., Lamaziere A., Tome S., Despres G., Matos C.A., Mechmet F., Langui D., Dunnen W. et al. (2019) Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathol., 138, 837&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">31197505</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbu A., Hamad O.A., Lind L., Ekdahl K.N. and Nilsson B. (2015) The role of complement factor C3 in lipid metabolism. Mol. Immunol., 67, 101&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">25746915</ArticleId></ArticleIdList></Reference><Reference><Citation>Foronjy R.F., Taggart C.C., Dabo A.J., Weldon S., Cummins N. and Geraghty P. (2015) Type-I interferons induce lung protease responses following respiratory syncytial virus infection via RIG-I-like receptors. Mucosal Immunol., 8, 161&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4268269</ArticleId><ArticleId IdType="pubmed">25005357</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L., Li Y., Jia L., Qin Y., Qi G., Cheng J., Qi Y., Li H. and Du J. (2012) Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS One, 7, e35315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340377</ArticleId><ArticleId IdType="pubmed">22558139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Becker C., Reyes C. and Underhill D.M. (2014) Cutting edge: FYCO1 recruitment to dectin-1 phagosomes is accelerated by light chain 3 protein and regulates phagosome maturation and reactive oxygen production. J. Immunol., 192, 1356&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966112</ArticleId><ArticleId IdType="pubmed">24442442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.Y., Pfluger C.M., Henderson R.D. and McCombe P.A. (2012) Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis. J. Neuroimmunol., 249, 93&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22633272</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Thezenas M.L., Charles P.D., Evetts S., Hu M.T., Talbot K., Fischer R., Kessler B.M. and Turner M.R. (2018) Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann. Neurol., 83, 258&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Lombardi V. and Malaspina A. (2018) Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol., 84, 130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Pfluger C., Singh P., Lim C.Y., Airey C. and Henderson R.D. (2015) Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. J. Neurol. Sci., 353, 122&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25958264</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P. and Horvath S. (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 9, 559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>